Dr. Aparicio is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1155 Pressler Street
CPB 7.3512, Unit 1374
Houston, TX 77030Phone+1 713-792-2830Fax+1 713-745-0422- Is this information wrong?
Education & Training
University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2000 - 2002
UCLA-VA Greater Los AngelesResidency, Internal Medicine, 1997 - 2000
Autonomous University of Madrid Class of 1995
Certifications & Licensure
FL State Medical License 2021 - Present
CA State Medical License 1999 - Present
TX State Medical License 2006 - 2025
OK State Medical License 2020 - 2021
Clinical Trials
- Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer Start of enrollment: 2006 May 01
- Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma Start of enrollment: 2007 Oct 01
- Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2016 May 18
- Join now to see all
Publications & Presentations
PubMed
- Integrative molecular analyses of the MD Anderson prostate cancer patient-derived xenograft (MDA PCa PDX) series.Nicolas Anselmino, Estefania Labanca, Peter D A Shepherd, Jiabin Dong, Jun Yang, Xiaofei Song, Subhiksha Nandakumar, Ritika Kundra, Cindy J Lee, Nikolaus Schultz, Jian...> ;Clinical Cancer Research. 2024 Mar 15
- 1 citationsNoninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation.Gian Marco Franceschini, Orsetta Quaini, Kei Mizuno, Francesco Orlando, Yari Ciani, Sheng-Yu Ku, Michael Sigouros, Emily Rothmann, Alicia Alonso, Matteo Benelli, Cater...> ;Cancer Discovery. 2024 Mar 1
- Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments.Slack-Tidwell, R., Zhu, K., San Lucas, F., Siddiqui, B., Soundararajan, R., Viscuse, P., Zhang, M., Rohra, P., Konnick, E., Pilie, P., Logothetis, C., Corn, P., Subudh...> ;Cancers. 2023 Dec 14
- Join now to see all
Press Mentions
Paul Viscuse, MD, on Androgen-Indifferent Prostate CancersSeptember 8th, 2021- Treatment Sequencing in Castrate-Resistant Metastatic Cancer - Mark FlemingJune 9th, 2021
- Two-Time Cancer Survivor: MD Anderson Is Helping Me Beat the OddsDecember 1st, 2020
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
University of Texas M.D. Anderson Cancer CenterHouston, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
